GlaxoSmithKline (NYSE:GSK) was upgraded by research analysts at Barclays from an “equal weight” rating to an “overweight” rating in a research note issued on Tuesday, The Fly reports.

Several other research firms also recently commented on GSK. Zacks Investment Research upgraded GlaxoSmithKline from a “hold” rating to a “buy” rating and set a $46.00 target price for the company in a research report on Wednesday, October 18th. JPMorgan Chase & Co. restated a “neutral” rating on shares of GlaxoSmithKline in a research report on Wednesday, October 18th. Bank of America downgraded GlaxoSmithKline from a “buy” rating to a “neutral” rating in a research report on Thursday, October 26th. UBS Group restated a “buy” rating on shares of GlaxoSmithKline in a research report on Monday. Finally, TheStreet upgraded GlaxoSmithKline from a “c+” rating to a “b” rating in a research report on Wednesday, October 25th. Three equities research analysts have rated the stock with a sell rating, ten have given a hold rating and six have issued a buy rating to the company. GlaxoSmithKline has a consensus rating of “Hold” and a consensus price target of $38.57.

GlaxoSmithKline (GSK) traded up $0.66 during trading on Tuesday, hitting $37.50. The company had a trading volume of 4,999,600 shares, compared to its average volume of 6,065,456. The company has a debt-to-equity ratio of 2.96, a current ratio of 0.64 and a quick ratio of 0.44. The company has a market cap of $93,290.00, a P/E ratio of 28.63, a PEG ratio of 2.15 and a beta of 0.97. GlaxoSmithKline has a 1-year low of $34.52 and a 1-year high of $44.53.

GlaxoSmithKline (NYSE:GSK) last posted its earnings results on Wednesday, October 25th. The pharmaceutical company reported $0.85 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.84 by $0.01. GlaxoSmithKline had a return on equity of 115.30% and a net margin of 7.79%. sell-side analysts anticipate that GlaxoSmithKline will post 2.9 EPS for the current year.

In other GlaxoSmithKline news, major shareholder Plc Glaxosmithkline acquired 428,571 shares of the business’s stock in a transaction on Monday, November 6th. The stock was purchased at an average price of $14.00 per share, for a total transaction of $5,999,994.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 10.00% of the company’s stock.

A number of institutional investors and hedge funds have recently modified their holdings of the business. Atria Investments LLC raised its position in GlaxoSmithKline by 17.1% in the 4th quarter. Atria Investments LLC now owns 12,830 shares of the pharmaceutical company’s stock valued at $455,000 after purchasing an additional 1,874 shares during the last quarter. KCS Wealth Advisory bought a new position in GlaxoSmithKline in the 4th quarter valued at $461,000. Trust Co increased its stake in shares of GlaxoSmithKline by 13.0% in the 3rd quarter. Trust Co now owns 28,634 shares of the pharmaceutical company’s stock valued at $1,163,000 after buying an additional 3,285 shares during the period. Bogart Wealth LLC increased its stake in shares of GlaxoSmithKline by 11.9% in the 4th quarter. Bogart Wealth LLC now owns 40,495 shares of the pharmaceutical company’s stock valued at $1,436,000 after buying an additional 4,310 shares during the period. Finally, Atlantic Trust Group LLC increased its stake in shares of GlaxoSmithKline by 20.3% in the 3rd quarter. Atlantic Trust Group LLC now owns 69,783 shares of the pharmaceutical company’s stock valued at $2,834,000 after buying an additional 11,777 shares during the period. Hedge funds and other institutional investors own 9.80% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “GlaxoSmithKline (GSK) Raised to Overweight at Barclays” was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another publication, it was illegally copied and republished in violation of U.S. & international trademark and copyright legislation. The correct version of this story can be viewed at https://www.americanbankingnews.com/2018/01/16/glaxosmithkline-gsk-raised-to-overweight-at-barclays.html.

GlaxoSmithKline Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

The Fly

Analyst Recommendations for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.